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The predictive value of changes in the severity of
electrocardiographic left ventricular hypertrophy (ECG-
LVH) during antihypertensive therapy remains unclear in
isolated systolic hypertension (ISH). In a Losartan
Intervention For Endpoint reduction in hypertension
substudy, we included 1320 patients aged 54–83 years
with systolic blood pressure (BP) of 160–200mmHg,
diastolic BP o90mmHg and ECG-LVH by Cornell
voltage-duration product and/or Sokolow–Lyon voltage
criteria, randomized to losartan- or atenolol-based
treatment with a mean follow-up of 4.8 years. The
composite end point of cardiovascular death, non-fatal
myocardial infarction (MI) or stroke occurred in 179
(13.6%) patients. In Cox regression models controlling
for treatment, Framingham risk score, as well as base-
line and in-treatment BP, less severe in-treatment ECG-
LVH by Cornell product and Sokolow–Lyon voltage was
associated with 17 and 25% risk reduction for the
composite end point (adjusted hazard ratio (HR) 0.83,
95% confidence interval (95% CI:) 0.75–0.92, P¼ 0.001
per 1050mmms (1 s.d.) lower Cornell product; and HR
0.75, 95% CI: 0.65–0.87, Po0.001 per 10.5mm (1 s.d.)
lower Sokolow–Lyon voltage). In parallel analyses,
lower Cornell product and Sokolow–Lyon voltage were
associated with lower risks of cardiovascular mortality
and MI, and lower Sokolow–Lyon voltage with lower risk
of stroke. Lower Cornell product and Sokolow–Lyon
voltage during antihypertensive therapy are associated
with lower likelihoods of cardiovascular events in
patients with ISH.
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Introduction
Isolated systolic hypertension (ISH), the most com-
mon form of hypertension in the elderly, is associated
with increased risk of cardiovascular morbidity and
mortality compared with isolated diastolic hyperten-
sion,1,2 and antihypertensive treatment is efficacious.3
Left ventricular hypertrophy (LVH) detected by
12-lead electrocardiogram (ECG)4–7 and by echocar-
diography8–13 are common manifestations of pre-
clinical cardiovascular disease that strongly predict
cardiovascular morbidity and mortality. Antihyper-
tensive therapy targeted at decreasing blood pres-
sure (BP) can produce regression of LVH,5,12,14–20 and
reduce, but do not entirely eliminate, the increased
risk of major cardiovascular events.21–25 Low sensi-
tivity (13–31%) of standard voltage criteria (Soko-
low–Lyon voltage) for the detection of anatomical
LVH has limited the use of ECG for detection of
LVH and for serial evaluation of changes in the left
ventricular mass.26–34 However, the use of Cornell
voltage-duration product enhances sensitivity of
the ECG to 51%, with a matched specificity of
95%.26,27,29–31
As previously described in the Losartan Interven-
tion For Endpoint reduction in hypertension (LIFE)
study,35–39 lower in-treatment values of both Cornell
voltage-duration product and Sokolow–Lyon voltage
during antihypertensive therapy were strongly asso-
ciated with decreased risk of the composite end
point of cardiovascular death, myocardial infarction
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(MI) or stroke and its individual components,
independent of treatment effect, baseline Framing-
ham risk score,40 baseline and in-treatment BP, as
well as severity of baseline ECG-LVH. Furthermore, in
a comparative report on cardiovascular outcomes
in ISH patients with ECG-LVH, a LIFE substudy
demonstrated significantly lower rates of stroke
and cardiovascular death in patients randomized
to losartan- versus atenolol-based antihypertensive
therapy.41
However, the effect of reducing ECG-LVH during
antihypertensive therapy remains unclear in pa-
tients with ISH. The aim of this pre-specified
substudy of LIFE was to investigate the effect of
lower in-treatment ECG-LVH for cardiovascular
morbidity and mortality in patients with ISH, and
whether this effect was stronger in patients with ISH
than in patients with systolic–diastolic hyperten-
sion or isolated diastolic hypertension.
Materials and methods
Study design and target population
As described in detail elsewhere,35–38 the LIFE study
enrolled 9193 patients with essential hypertension
(mean seated BP in the range of 160–200mmHg
systolic, 90–115mmHg diastolic or both) having
ECG-LVH determined by the Cornell voltage-dura-
tion product29,30 and/or the Sokolow–Lyon voltage
criteria32 on a screening ECG in a prospective,
double-blind, parallel group study with randomiza-
tion to losartan- versus atenolol-based therapy. The
main outcome was the composite of cardiovascular
death, non-fatal stroke and non-fatal MI. Secondary
outcome measures included the components of the
primary composite end point (cardiovascular death,
all strokes and all MIs). Patients were followed up
forX4 years with regular visits and upward titration
of medication targeting a BP level of p140/
90mmHg.35
The data presented in this study were obtained
from 1320 patients (14.4%) with ISH, a subgroup
pre-specified in the original LIFE data analysis plan
as having systolic BP X160mmHg and diastolic BP
o90mmHg after 1–2 weeks of receiving placebo.
The trial protocol was approved by all ethics
committees concerned, in accordance with the
Declaration of Helsinki, and was overseen by an
independent data and safety monitoring board, and
all patients gave written informed consent. All study
data reside in a database with the authors.
Electrocardiography
ECGs were obtained at study baseline, at 6 months
and at yearly follow-up intervals until study termina-
tion or patient death. All ECGs were read at the core
laboratory at the Sahlgrenska University Hospital/
O¨stra, Go¨teborg, Sweden, by experienced readers
blinded to clinical information. QRS duration was
measured to the nearest 4ms and the QRS amplitudes
to the nearest 0.5mm (0.05mV). The product of QRS
duration the Cornell voltage combination (RaVLþ
SV3, with 8mm added in women
29,30) was used with a
threshold value of 2440mmms to identify LVH.
The sex adjustment of Cornell voltage was reduced
from 8 to 6mm, and Sokolow–Lyon voltage (SV1þRV5/6)
438mm was accepted for electrocardiographic
eligibility in patients recruited after 30 April 1996
(n¼ 7708 in the LIFE study, including 1003 in the
ISH substudy). The rationale for these changes in
ECG entry criteria has been described in detail.36,39
Statistical analyses
Statistical analyses were performed using SPSS
version 16.0 (SPSS Inc., Chicago, IL, USA). Data
are presented as mean±s.d. for continuous variables
and as proportions for categorical variables. Com-
parison among annual measurements of mean BP
and ECG-LVH was performed using mixed-effects
linear models to account for the within-subject
correlation. As previously described,39 possible
associations between ECG-LVH voltage during
antihypertensive therapy and the risk of developing
the LIFE composite end point and its individual
components were analyzed according to a pre-
specified statistical analysis plan using Cox
proportional hazard models42 and based on the
intention-to-treat principle.37 Baseline and
subsequent determinations of Cornell product and
Sokolow–Lyon voltage were entered as time-varying
covariates in the Cox models. ECGs undertaken
after a non-fatal event were excluded from further
time-varying analyses regarding the end point in
question. Baseline Framingham risk score and a
treatment group indicator were included as standard
covariates, and baseline and subsequent systolic and
diastolic BP measurements were entered as time-
varying covariates. The adjusted hazard ratios (HRs)
for the incidence of the composite end point and its
components for Cornell product and Sokolow–Lyon
voltage treated as continuous variables were com-
puted per 1-s.d.-of-the-mean lower values of the
ECG criteria as the antilogarithm of the estimated
coefficient multiplied by the s.d.43 The 95% con-
fidence intervals (95% CIs) of HRs were calculated
from the estimated coefficients and their s.e.,44 and
Wald w2 statistics and probability values were
calculated. In coherence with previous analyses,
the baseline s.d. for the whole LIFE population was
used in the calculations; 1050mmms for Cornell
product and 10.5mm for Sokolow–Lyon voltage.39
To test whether the effect of reduced ECG-LVH on
the composite end point was stronger in ISH
patients compared with non-ISH patients, inter-
action analyses were performed using Cox propor-
tional hazard models on the entire LIFE cohort
and entering ISH status as a categorical covariate
and either Sokolow–Lyon criteria or Cornell product
as a time-varying covariate and the cross-product of
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ISH status and either time-varying Sokolow–Lyon
criteria or Cornell product as a continuous covariate.
The P-value of this interaction cross-product was
used to determine whether there was a positive
interaction, that is, whether ISH increased the
outcome effect of the reduction in the ECG indices.
A two-tailed Po0.05 was required for statistical
significance.
Results
Characteristics of ISH and non-ISH patients are
presented in Table 1. ISH patients were aged 54
through 83 years (mean 70 years) and the mean
follow-up time was 4.8±0.9 years. The primary end
point, a composite of cardiovascular death, non-fatal
MI or non-fatal stroke occurred in 179 (13.6%) of 1320
patients with ISH during 6146 patient-years follow-up
(Figure 1). Fatal/non-fatal stroke, fatal/non-fatal MI
and cardiovascular death occurred in 88 (6.7%), 67
(5.1%) and 79 (6.0%) patients, respectively.
Serial assessment of BP and ECG-LVH
Baseline and follow-up mean systolic and diastolic
BP and ECG-LVH by Cornell voltage-duration
product and Sokolow–Lyon voltage, are presented
in Figures 2a and b. Mean Cornell voltage (mmms)
values (s.d.) at baseline, and year 1 through year 5,
were 2792 (1101), 2700 (1154), 2607 (1106), 2605
(1109), 2613 (1187) and 2632 (1113). Similarly, mean
Sokolow–Lyon voltage (mm) values (s.d.) at base-
line, and year 1 through year 5, were 31.0 (10.4),
29.1 (9.8), 28.3 (9.9), 27.7 (9.9), 27.3 (9.5) and 26.9
(9.4). As previously reported for the total LIFE
population,39 for ISH patients, there were also
Table 1 Characteristics of patients with and without isolated systolic hypertensiona
Characteristics at baseline ISH patients (n¼1320) Non-ISH patients (n¼ 7873)
Age, years 70.3 (6.3) 66.4 (7.0)
Women, no. (%) 794 (60.2%) 4169 (53.0%)
Ethnicity, no. (%)
White 1217 (92.2%) 7286 (92.5%)
Black 81 (6.1%) 452 (5.7%)
Hispanic 14 (1.1%) 86 (1.1%)
Asian 6 (0.5%) 37 (0.5%)
Other 2 (0.2%) 12 (0.2%)
Smoking, no. (%)
Never 661 (50.1%) 3995 (50.7%)
Ex-smoker 464 (35.2%) 2569 (32.6%)
Current smoker 194 (14.7%) 1305 (16.6%)
Blood pressure, mmHg
Systolic 174 (11) 174 (15)
Diastolic 83 (6) 100 (6)
Heart rate, beats per min 72 (11) 74 (11)
Body mass index, kgm2 27.5 (4.9) 28.1 (4.8)
Framingham risk score, 5-year event rate, % 23.2 (9.95) 22.3 (9.33)
Cornell product, mmms 2792 (1101) 2829 (1020)
Sokolow–Lyon voltage, mm 31.0 (10.4) 29.8 (10.3)
Medical history, no. (%)
Previously untreated hypertension 440 (33.3%) 2116 (26.9%)
Myocardial infarction 116 (8.8%) 453 (5.8%)
Coronary heart disease 295 (22.3%) 1174 (14.9%)
Cerebrovascular disease 156 (11.8%) 572 (7.3%)
Peripheral vascular disease 111 (8.4%) 409 (5.2%)
Diabetes mellitus 234 (17.7%) 961 (12.2%)
Atrial fibrillation 66 (5.0%) 258 (3.3%)
Abbreviation: ISH, isolated systolic hypertension.
aData are presented as mean (s.d.) unless otherwise indicated.
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Figure 1 Incidence of cardiovascular morbidity and mortality in
patients with isolated systolic hypertension (ISH) over a mean
follow-up of 4.8 years.
ISH and ECG-LVH
ACK Larstorp et al
180
Journal of Human Hypertension
significant decreases (Po0.001) in mean systolic
and diastolic BP, Cornell product and Sokolow–
Lyon voltage during follow-up, as a consequence of
protocol-based antihypertensive therapy.
ECG-LVH and cardiovascular events
In Cox regression models controlling only for treat-
ment with atenolol or losartan, lower in-treatment
Sokolow–Lyon voltage was significantly associated
with lower rates of the composite end point (HR 0.72,
95% CI: 0.63–0.83, Po0.001 per 10.5mm (1 s.d.)
lower Sokolow–Lyon voltage) and cardiovascular
death (HR 0.67, 95% CI: 0.54–0.83, Po0.001 per
1 s.d. lower Sokolow–Lyon voltage), fatal/non-fatal
MI (HR 0.77, 95% CI: 0.61–0.97, P¼ 0.025 per 1 s.d.
lower Sokolow–Lyon voltage) and fatal/non-fatal
stroke (HR 0.71, 95% CI: 0.58–0.87, P¼ 0.001 per 1
s.d. lower Sokolow–Lyon voltage). In parallel ana-
lyses, lower in-treatment Cornell product was asso-
ciated with lower rates of the composite end
point (HR 0.83, 95% CI: 0.74–0.92, Po0.001 per
1050mmms (1 s.d.) lower Cornell product), cardio-
vascular death (HR 0.74, 95% CI: 0.64–0.85, Po0.001
per 1 s.d. lower Cornell product) and MI (HR 0.83,
95% CI: 0.70–0.98, P¼ 0.03 per 1 s.d. lower Cornell
product), but not stroke (HR 0.99, 95% CI: 0.83–1.18,
P¼ 0.91 per 1 s.d. lower Cornell product). In addi-
tional models adjusting for treatment, baseline
Framingham risk score, as well as baseline and in-
treatment systolic and diastolic BP, the results
were largely unaltered (Figure 3). A 1050mmms
(1 s.d.) lower Cornell product was associated with a
17% (95% CI: 8–25%) lower risk of the composite
cardiovascular end point (P¼ 0.001), a 25% (95%
CI: 14–35%) lower risk of cardiovascular death
(Po0.001) and a 17% (95% CI: 2–30%) lower risk
of MI (P¼ 0.028). A 10.5mm (1 s.d.) lower Sokolow–
Lyon voltage was associated with a 25% (95% CI:
13–35%) lower risk of the composite cardiovascular
end point (Po0.001), a 28% (95% CI: 11–42%)
lower risk of cardiovascular death (P¼ 0.003), a 23%
(95% CI: 2–39%) lower risk of MI (P¼ 0.037) and a
25% (95% CI: 7–39%) lower risk of stroke (P¼ 0.008).
The interaction analyses between ISH status (ISH
versus non-ISH) and time-varying ECG-LVH, sho-
wed a significant interaction between lower time-
varying Sokolow–Lyon voltage and lower risk of the
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Figure 2 (a) Systolic and diastolic blood pressure: significant
overall reduction from baseline to year 5 (Po0.001). Data are
presented as mean (s.d.). (b) Electrocardiographic left ventricular
hypertrophy was significantly reduced from baseline to year 5.
Data are presented as mean (s.d.).
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Figure 3 Forest plot: results of Cox proportional hazards models with Cornell product and Sokolow–Lyon voltage as time-varying
covariates in examining cardiovascular morbidity and mortality in patients with isolated systolic hypertension. Results were adjusted for
treatment effect, baseline Framingham risk score and systolic and diastolic blood pressures at baseline and during treatment. ISH,
isolated systolic hypertension; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction. *HRs calculated per 1 s.d. decrease in
Cornell product (1050mmms) and Sokolow–Lyon voltage (10.5mm).
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composite end point in ISH versus non-ISH patients
(P¼ 0.048), that is, ISH patients had an increased
outcome effect of reduced time-varying Sokolow–
Lyon voltage compared with non-ISH patients.
When time-varying systolic BP was added to the
model with ISH status and time-varying Sokolow–
Lyon criteria, the interaction product of ISH status
and time-varying Sokolow–Lyon criteria was border-
line significant (P¼ 0.06). Not surprisingly, time-
varying systolic BP is a strong predictor of the
composite end point and a very strong covariate in
the above-mentioned regression model. There was
no significant interaction between ISH status and
the time-varying Cornell product.
Discussion
In this pre-specified prospective substudy in pa-
tients with ISH and LVH, we found significant
associations between lower in-treatment ECG-LVH
by Cornell voltage-duration product or Sokolow–
Lyon voltage and reduced risk of the composite end
point of cardiovascular death, non-fatal MI or non-
fatal stroke. Similarly, we found significant associa-
tions between lower in-treatment ECG-LVH and
reduced risk of cardiovascular mortality and MI.
Furthermore, lower in-treatment Sokolow–Lyon vol-
tage was associated with lower risk of stroke. These
results were independent of treatment modality,
baseline and in-treatment BP and baseline Framing-
ham risk score. Interaction analyses between
ECG-LVH and ISH status identified a significant
interaction between lower in-treatment Sokolow–
Lyon voltage and lower risk of the composite end
point in patients with ISH as compared with those
without ISH.
To our knowledge, this is the first study to report a
strong, independent association between lower in-
treatment ECG-LVH and reduced risk of cardiovas-
cular morbidity and mortality in patients with ISH.
LVH demonstrated by ECG and echocardiography is
a strong predictor of cardiovascular disease, parti-
cularly of cerebrovascular events;45 and studies have
shown that prevention and regression of both
indices of LVH are associated with reduced risk of
cardiovascular disease.4,5,19,23,39,46 Predicting the out-
come by echocardiography was proven by Levy
et al.,9 but to show that regression of LVH translates
into improved prognosis, we needed statistical
power and a larger number of participants, which
was feasible to recruit by ECG only. In particular,
this was the case for patients with ISH, which
constituted 14.4% of the LIFE population recruited
by ECG-LVH. ISH patients were somewhat older
than non-ISH patients (Table 1), but the difference
was only 3.9 years on average, and overall there is
quite minimal overlap between the elderly LIFE
participants previously discussed47 and the ISH sub-
population included in this study. There is a lot of
focus on ISH as a particular subgroup of hyperten-
sive patients with stiffer large arteries and worse
prognosis, that is, more advanced disease.3 In LIFE,
the ISH subgroup was therefore pre-specified in the
data analysis protocol as a group of particular
interest,41 a hypothesis that we pursued in this
study. In the main LIFE study, the predictive power
of lower in-treatment echo-LVH46 was similar to the
predictive power of lower in-treatment ECG-LVH.
Unfortunately, the number of patients with ISH in
the echocardiography substudy (n¼ 145) was too
small to produce any meaningful results for in-
treatment echo-LVH.
Our results also suggest superior performance for
Sokolow–Lyon voltage LVH compared with Cornell
voltage-duration product LVH for prediction of
cardiovascular end points in patients with ISH
compared with patients without ISH. A possible
explanation for this may be that Sokolow–Lyon
voltage LVH is strongly associated with systolic BP
and therefore ISH, whereas Cornell product LVH is
more related to metabolic risk factors.48 In addition,
a possible explanation for the better performance of
the Sokolow–Lyon voltage, which is easier to use in
clinical practice than the Cornell product, may be
sought in the way these criteria were originally
developed. It seems that in the Veteran Administra-
tion population of hypertensive patients who were
investigated for the development of the Sokolow–
Lyon ECG-LVH criteria, a majority of patients had
quite severe hypertension with a high contribution
of patients with ISH.32 Our data indicate that the
regression of ECG-LVH by Cornell voltage-duration
product may reach a nadir earlier than the regres-
sion of ECG-LVH by Sokolow–Lyon voltage in
patients with ISH (Figure 2b). Again, this is possibly
explained by the two ECG-LVH criteria characterizing
somewhat different LVH populations; Sokolow–Lyon
more patients with concentric LVH and Cornell more
patients with eccentric LVH;46 these populations may
respond somewhat differently to antihypertensive
treatment with respect to regression of LVH. Normal-
ization of the ECG should be sought in all hyperten-
sive patients with ECG-LVH to improve their
prognosis, and according to our present data for
patients with ISH, this is even more so in the case of
having Sokolow–Lyon criteria on ECG.
The association between lower in-treatment LVH
and reduced risk of cardiovascular events partly
explains our previous report in which treatment
with losartan, regardless of similar BP reductions,
resulted in lower cardiovascular morbidity and
mortality compared with atenolol in patients with
ISH, as we found that losartan was more effective in
reducing LVH.41 Furthermore, our data complement
a recent report from the LIFE study indicating that
there were significantly higher risks for the primary
composite end point, stroke and total mortality in
the highest versus lowest quartile of baseline pulse
pressure with atenolol-based treatment. The risks in
the losartan group also increased with increasing
pulse pressure quartile, but were lower than those in
ISH and ECG-LVH
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the atenolol group, and were not significant.49 Our
study also complements results from the SCOPE
(Study on Cognition and Prognosis in the Elderly)
substudy including 1518 patients with ISH, in
which candersartan-based treatment resulted in a
42% (P¼ 0.049) risk reduction for stroke in compar-
ison with other antihypertensive treatment, despite
small differences in BP lowering.50 Finally, data
from a substudy of the ASCOT (Anglo-Scandinavian
Cardiac Outcomes Trial) trial, indicated that central
aortic BP may especially be an important determi-
nant of cardiovascular outcomes,51 and one could
speculate that this effect is even more profound in
patients with ISH because of higher arterial stiffness.
In conclusion, lower in-treatment LVH deter-
mined by Cornell voltage-duration product and
Sokolow–Lyon voltage, was associated with lower
likelihoods of cardiovascular morbidity and mortal-
ity, independent of BP lowering, baseline Framing-
ham risk score and treatment modality in patients
with ISH. These results indicate that targeting
antihypertensive treatment at regression or preven-
tion of ECG-LVH, and beyond that of lowering BP,
may reduce cardiovascular morbidity and mortality
in patients with ISH. This study supports serial
measurements of ECG-LVH, and in particular Soko-
low–Lyon voltage, for risk stratification in patients
with ISH undergoing antihypertensive therapy.
However, further investigations may be necessary
to evaluate whether treatment should be targeted at
regression of ECG-LVH in patients with ISH, and not
only at specific BP values.
Limitations
There are several limitations to this study; this is a
substudy in patients with ISH in the LIFE study;
however, ISH patients were selected a priori as being
of special interest. Patients evaluated in the LIFE
study were predominantly White. Patients included
had hypertension and ECG-LVH, and thus represent
a patient population with increased risk of cardio-
vascular events compared with hypertensive sub-
jects without LVH; the results may not extend to ISH
patients without LVH. In addition, patients with ISH
and ECG-LVH were at an even higher baseline risk
than the other hypertensive subjects with LVH.
Furthermore, as noted previously by Okin et al.,39
the phenomenon of regression to the mean52 may
affect the current findings, with regard to the use of
values of Cornell product and Sokolow–Lyon vol-
tage above threshold levels to select patients for the
LIFE study, despite our attempt to minimize this
problem by using separate screening and baseline
ECGs.35,36 Owing to this selection process and the
intrinsic variability of ECG measurements,52–55 it is
likely that both the degree of ECG-LVH at baseline
and the subsequent decrease in LVH during therapy
were overestimated in some patients. Despite these
limitations, improved outcome was associated with
lower ECG-LVH, which would actually bias against
our findings, because these overestimations due to
statistical fluctuations would lead to a more con-
servative estimate of the effect of ECG-LVH on
outcome. Furthermore, assessment of risk based on
ECG-LVH criteria considered as time-varying covari-
ates adjusts for both baseline and subsequent levels
of these variables, mitigating the effect of any
overestimations.39 There was no significant associa-
tion between lower ECG-LVH by Cornell voltage-
duration product and stroke (P¼ 0.96). This result
may represent type II error due to lack of power; the
LIFE study was designed for the primary composite
end point, and not for its components. As a
consequence, the HRs for the single end points
cardiovascular mortality, all MIs and all strokes
require careful interpretation.
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